Search - tctmd.com

Displaying 461 - 480 of 867

Sort: Relevancy | Date

Presentation THT 2022

Clinical Trials During COVID-19: Innvestigator Perspective

Presenter: Scott Solomon

February 02, 2022

Presentation THT 2022

Research Consortium / Collabratories

Presenter: Mona Fiuzat

February 02, 2022

Presentation THT 2022

Challenges With Cardiogenic Shock Studies in the US

Presenter: Chuck Simonton

February 02, 2022

Presentation THT 2022

Innovation in Heart Failure Trial Designs

Presenter: Ori Ben-Yehuda

February 02, 2022

Presentation THT 2022

Heart Failure Trials in the Modern Era: Where Are We Going?

Presenter: Andrew Farb

February 02, 2022

Presentation THT 2022

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

Presenter: Akshay Desai

February 02, 2022

News Industry News

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

February 02, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

Presentation THT 2022

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Presenter: Barry Greenberg

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Presenter: Milton Packer

February 01, 2022

Presentation THT 2022

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Presenter: John Teerlink

February 01, 2022

Presentation THT 2022

Secubitirl-Valsartan Across the Spectrum of EFs

Presenter: Scott Solomon

February 01, 2022

Presentation THT 2022

Vericiguat

Presenter: Javed Butler

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors: What the Clinician Should Know

Presenter: Stefan Anker

February 01, 2022

News Opinion CV Team Dispatch

February 2022 News Roundup

L.A. McKeown

February 01, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

Todd Neale

January 26, 2022

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Todd Neale

January 21, 2022

News Opinion Fellow Talk

A Trainee’s Perspective on the First Genetically Engineered Pig-to-Human Cardiac Xenotransplantation

Corbin E. Goerlich, MD

January 13, 2022

Advertisement

Clinical Trials During COVID-19: Innvestigator Perspective

Research Consortium / Collabratories

Challenges With Cardiogenic Shock Studies in the US

Innovation in Heart Failure Trial Designs

Heart Failure Trials in the Modern Era: Where Are We Going?

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Secubitirl-Valsartan Across the Spectrum of EFs

Vericiguat

SGLT2 Inhibitors: What the Clinician Should Know

February 2022 News Roundup

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

A Trainee’s Perspective on the First Genetically Engineered Pig-to-Human Cardiac Xenotransplantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content